According to Israeli news site calcalist.co.il, Teva Pharmaceutical Co. is evaluating a potential acquisition of biotech company Avanir Pharmaceuticals (AVNR).

The article appears in Hebrew, but a quick translation through our trusty Google Translate function says this (no edits):

Explores the nature of the acquisition Znwih (Zenvia) develops and Avnir (Avanir). Recently, Teva began reviewing appropriateness company Hnshrt Hnasd”k on the stock exchange by value of 145 million dollars. Coin was not response.

Hznwih is intended for the treatment of pain Noirofti Patients with diabetes, stroke and patients affected by traumatic injury panel. Medicine is the third and final stage of clinical trials (Phase III).

Since the completion of the acquisition of a well, at the end of 2008 made no new purchases of nature. However, over the statement period, senior company intend to make a purchase.

The story first appeared on The Marker, but the news has yet to make headlines in the U.S.

The story was first reported by yael.pollak@themarker.com.

AVNR is developing Zenvia, a Phase III clinical development stage product for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain).

Stay tuned…

No positions

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts